Premium
Intravenous leiomyomatosis treated with radical hysterectomy and adjuvant aromatase inhibitor therapy
Author(s) -
Mizoguchi Chiharu,
Matsumoto Harunobu,
Nasu Kaei,
Arakane Motoki,
Kai Kentaro,
Narahara Hisashi
Publication year - 2016
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.13063
Subject(s) - medicine , aromatase inhibitor , uterine leiomyoma , hysterectomy , leiomyoma , aromatase , adjuvant therapy , hormonal therapy , surgical menopause , surgery , radiology , menopause , breast cancer , cancer , chemotherapy
Intravenous leiomyomatosis (IVL), a rare disease that is histologically benign but clinically aggressive, is characterized by the intraluminal growth of benign leiomyoma in the intrauterine and systemic veins. Preoperative diagnosis of IVL is difficult, because the symptoms of early stage IVL are similar to those of uterine leiomyoma. The efficacy of adjuvant hormone therapy after surgical resection of IVL remains unclear. Herein is described a case of IVL that was diagnosed preoperatively, in which successful total resection of the tumor was achieved by radical hysterectomy. The patient, a 50‐year‐old premenopausal Japanese woman, also underwent aromatase inhibitor treatment and was free of disease at 36 months after surgery. Contrast‐enhanced computed tomography is suggested as the best assessment for identifying and diagnosing IVL. Radical hysterectomy can be considered a successful therapy for total resection. Aromatase inhibitor treatment may be effective, especially when the patient has not yet entered menopause.